Cargando…

Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.

Nabilone, a synthetic cannabinoid, and Prochlorperazine were compared in a double-blind crossover study of 34 patients with lung cancer undergoing a 3-day schedule of chemotherapy with Cyclophosphamide, Adriamycin and Etoposide. Symptom scores were significantly better for patients on nabilone for n...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmedzai, S., Carlyle, D. L., Calder, I. T., Moran, F.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1983
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011510/
https://www.ncbi.nlm.nih.gov/pubmed/6315040
_version_ 1782136544238239744
author Ahmedzai, S.
Carlyle, D. L.
Calder, I. T.
Moran, F.
author_facet Ahmedzai, S.
Carlyle, D. L.
Calder, I. T.
Moran, F.
author_sort Ahmedzai, S.
collection PubMed
description Nabilone, a synthetic cannabinoid, and Prochlorperazine were compared in a double-blind crossover study of 34 patients with lung cancer undergoing a 3-day schedule of chemotherapy with Cyclophosphamide, Adriamycin and Etoposide. Symptom scores were significantly better for patients on nabilone for nausea, retching and vomiting (P less than 0.05). Fewer subjects vomited with nabilone (P = 0.05) and the number of vomiting episodes was lower (P less than 0.05); no patients on nabilone required additional parenteral anti-emetic. More patients preferred nabilone for anti-emetic control (P less than 0.005). Adverse effects common with nabilone were drowsiness (57%), postural dizziness (35%) and lightheadedness (18%). Euphoria was seen in 14% and a "high" in 7%. Erect systolic blood pressure was lower in nabilone patients on Day 1 (P = 0.05) but postural hypotension was a major problem in only 7%. Nabilone is an effective oral anti-emetic drug for moderately toxic chemotherapy, but the range and unpredictability of its side-effects warrant caution in its use.
format Text
id pubmed-2011510
institution National Center for Biotechnology Information
language English
publishDate 1983
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20115102009-09-10 Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy. Ahmedzai, S. Carlyle, D. L. Calder, I. T. Moran, F. Br J Cancer Research Article Nabilone, a synthetic cannabinoid, and Prochlorperazine were compared in a double-blind crossover study of 34 patients with lung cancer undergoing a 3-day schedule of chemotherapy with Cyclophosphamide, Adriamycin and Etoposide. Symptom scores were significantly better for patients on nabilone for nausea, retching and vomiting (P less than 0.05). Fewer subjects vomited with nabilone (P = 0.05) and the number of vomiting episodes was lower (P less than 0.05); no patients on nabilone required additional parenteral anti-emetic. More patients preferred nabilone for anti-emetic control (P less than 0.005). Adverse effects common with nabilone were drowsiness (57%), postural dizziness (35%) and lightheadedness (18%). Euphoria was seen in 14% and a "high" in 7%. Erect systolic blood pressure was lower in nabilone patients on Day 1 (P = 0.05) but postural hypotension was a major problem in only 7%. Nabilone is an effective oral anti-emetic drug for moderately toxic chemotherapy, but the range and unpredictability of its side-effects warrant caution in its use. Nature Publishing Group 1983-11 /pmc/articles/PMC2011510/ /pubmed/6315040 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Ahmedzai, S.
Carlyle, D. L.
Calder, I. T.
Moran, F.
Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
title Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
title_full Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
title_fullStr Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
title_full_unstemmed Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
title_short Anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
title_sort anti-emetic efficacy and toxicity of nabilone, a synthetic cannabinoid, in lung cancer chemotherapy.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011510/
https://www.ncbi.nlm.nih.gov/pubmed/6315040
work_keys_str_mv AT ahmedzais antiemeticefficacyandtoxicityofnabiloneasyntheticcannabinoidinlungcancerchemotherapy
AT carlyledl antiemeticefficacyandtoxicityofnabiloneasyntheticcannabinoidinlungcancerchemotherapy
AT calderit antiemeticefficacyandtoxicityofnabiloneasyntheticcannabinoidinlungcancerchemotherapy
AT moranf antiemeticefficacyandtoxicityofnabiloneasyntheticcannabinoidinlungcancerchemotherapy